Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study

BACKGROUND: The coronavirus disease 19 (covid-19) pandemic has underscored the need to expedite clinical research, which may lead investigators to shift away from measuring patient-important outcomes (PIO), limiting research applicability. We aim to investigate if randomized controlled trials (RCTs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez-Mora, Mario A., Varela, Andrea Ramírez, Meneses-Echavez, Jose F., Bidonde, Julia, Angarita-Fonseca, Adriana, Siemieniuk, Reed A. C., Zeraatkar, Dena, Bartoszko, Jessica J., Brignardello-Petersen, Romina, Honarmand, Kimia, Rochwerg, Bram, Guyatt, Gordon, Yepes-Nuñez, Juan José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559914/
https://www.ncbi.nlm.nih.gov/pubmed/34724980
http://dx.doi.org/10.1186/s13643-021-01838-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559914/
https://www.ncbi.nlm.nih.gov/pubmed/34724980
http://dx.doi.org/10.1186/s13643-021-01838-8

Ejemplares similares